Oncologic efficacy and safety of stereotactic body radiotherapy for oligometastatic non-small cell lung cancer: a systemic meta-analysis.
Jae-Uk Jeong, Gyu Sang Yoo, Jong Hoon Lee et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed the efficacy and safety of stereotactic body radiotherapy (SBRT) for oligometastatic non-small cell lung cancer, including analyses by oligometastatic subtype and single-lesion prevalence. Quantitative synthesis of 18 studies involving 1,105 patients found pooled 2-year overall survival of 60.0% (95% CI, 50.4-68.8%), 1-year progression-free survival of 65.8% (95% CI, 52.7-76.8%), and 2-year local control of 74.2% (95% CI, 63.9-82.4%). Severe treatment-related toxicity occurred in 4.5%.
Key findings
- Pooled 2-year overall survival was 60.0% (95% CI, 50.4-68.8%).
- Pooled 1-year progression-free survival was 65.8% (95% CI, 52.7-76.8%), and 2-year local control was 74.2% (95% CI, 63.9-82.4%).
- Severe (grade ≥ 3) treatment-related toxicity occurred in 4.5%, predominantly radiation pneumonitis and esophagitis.
- Studies with > 59% single-metastatic lesions showed a borderline trend toward higher 2-year overall survival (67.5% vs. 47.8%, p = 0.069).
Why it matters
The pooled outcomes suggest that SBRT can provide substantial local control and survival in selected patients with oligometastatic NSCLC, while severe toxicity was uncommon in the included studies. The subtype and lesion-burden analyses also highlight that outcomes may differ across clinical presentations, an important consideration when interpreting aggregate estimates and planning further evaluation.
What to keep in mind
The synthesis combines 18 eligible studies; the abstract does not specify their designs or report study-level heterogeneity, limiting assessment of how comparable the pooled populations and treatment approaches were.